Higher-Dose Ozempic Now Spans a 2 mg Injection and Oral Tablets

What Happened

Ozempic has quietly grown into a higher-dose brand on two fronts, and regulatory records now show the full picture. The FDA first expanded the once-weekly injection beyond its original 1 mg ceiling in early 2022, adding a 2 mg maintenance dose on data from the phase 3 SUSTAIN FORTE program, which showed the higher strength delivered additional blood-sugar lowering in patients who needed it.

Then, in late January 2026, the agency approved Novo Nordisk's request to rename its higher-absorption oral semaglutide formulation — previously sold as Rybelsus — to Ozempic (semaglutide) tablets. Updated labeling published in August 2026 lists Ozempic tablets in 1.5 mg, 4 mg, and 9 mg strengths alongside the injections, meaning the brand now spans both formats.

Who Is Affected

• Adults with type 2 diabetes whose current regimen leaves them short of treatment goals — the population both dose expansions target.
• Patients who cannot or will not inject, who now have an Ozempic-branded tablet with roughly double the absorption of the older oral formulation.
• Customs and regulatory agencies screening counterfeit products, because the definition of a "real" Ozempic product just got wider.
• Researchers and buyers in the gray peptide market, who must now distinguish licensed tablets from unapproved "oral semaglutide" powders.

Timeline

• January 2022 — FDA approves the 2 mg weekly injectable dose based on SUSTAIN FORTE.
• December 2024 — FDA clears the higher-bioavailability oral semaglutide formulation (designated R2).
• October 2025 — The oral product gains an added indication: reducing major cardiovascular-event risk in high-risk adults with type 2 diabetes.
• January 2026 — FDA approves renaming the R2 formulation as Ozempic (semaglutide) tablets.
• August 2026 — Updated US labeling lists Ozempic tablets (1.5/4/9 mg) and a multi-dose injectable pen containing four 2 mg doses.

What This Means for Researchers

The brand expansion changes counterfeit detection. A few years ago, any "Ozempic pill" was by definition fake — no oral product existed. Today genuine Ozempic tablets exist in exactly three strengths, so authenticity analysis shifts from format to specifics: tablets in strengths outside 1.5, 4, and 9 mg, or injectable vials carrying Ozempic branding, remain unapproved products. The legitimate tablets also contain the absorption enhancer SNAC — a marker absent from gray-market semaglutide powders sold as "research peptides."

How to Verify Your Peptides

• Start with our overview of how peptide testing works — identity, purity, and endotoxin checks apply to semaglutide material whatever the label claims.
• The semaglutide purity and COA verification guide covers what a legitimate certificate of analysis should contain.
• A trusted third-party testing lab can independently confirm whether "Ozempic" material is actually pharmaceutical semaglutide.

Safe Alternatives

If you research incretin compounds, our compound profiles for semaglutide and tirzepatide summarize the published evidence, and our vendor directory ranks suppliers by transparency signals such as published batch testing.

Sources

• Regulatory announcements (US prescribing information and approval records, 2022–2026)
• Industry reports (September 2026)